Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Ther Pat. 2014 Mar;24(3):355-60. doi: 10.1517/13543776.2014.871526. Epub 2014 Jan 3.

Aminothienopyridazines as imaging probes of tau pathology: a patent evaluation of WO2013090497.

Author information

1
University of Pennsylvania, Perelman School of Medicine, Center for Neurodegenerative Disease Research , 3600 Spruce Street, Philadelphia, PA 19104-6323 , USA bcarlo@sas.upenn.edu.

Abstract

Small-molecule ligands, amenable to positron emission tomography (PET) imaging of different types of neurodegenerative disease-associated amyloid deposits in the CNS of living patients, hold considerable promise for diagnostic purposes, as well as for monitoring disease progression and the effectiveness of treatments. The patent entitled 'Heterocyclic Compounds as Imaging Probes of Tau Pathology' (WO2013090497) discloses the identification of a novel class of tau imaging agents, the aminothienopyridazines. Selected compounds from this class are described that can stain selectively tau pathology in brain tissue sections. Moreover, examples of this class of compounds exhibit absorption, distribution, metabolism, excretion and pharmacokinetics (ADME-PK) properties that are appropriate for CNS PET ligands.

PMID:
24387030
PMCID:
PMC4399384
DOI:
10.1517/13543776.2014.871526
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center